Výsledky vyhledávání - "C Liberatoscioli"

EORTC 22071-24071

Autor: C. M. L. van Herpen, Denis Lacombe, Johannes A. Langendijk, C. Liberatoscioli, E. M. Ozsahin, R. Karra Gurunath, A. Gulyban, Wilfried Budach, N. Gosselin, Laurence Collette

Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 29(15_suppl):TPS197. AMER SOC CLINICAL ONCOLOGY

TPS197 Background: The clinical outcome of patients (pts) with resected HNSCC at high risk of recurrence remains poor. Disease free survival (DFS) at 5 years is around 40% after standard adjuvant chemoradiation (CRT). The use of anti-EGFR monoclonal

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1841f3c6e7203547ffa8b256d8e3d967
https://doi.org/10.1200/jco.2011.29.15_suppl.tps197

Zobrazit plný text záznamu

Cetuximab in recurrent and/or metastatic salivary gland carcinomas: A phase II study

Autor: F. Crippa, Laura D. Locati, S. Pilotti, Marta Orsenigo, Paolo Potepan, Paola Casieri, Paolo Bossi, Marco Losa, Lisa Licitra, Rosa Gioia Calderone, G. Rinaldi, Federica Perrone, Cristiana Bergamini, Luigi Mariani, Pasquale Quattrone, C. Liberatoscioli

EGFR overexpression in salivary gland carcinomas provides the rational for the investigation of anti-EGFR treatments in recurrent and/or metastatic salivary gland cancers (RMSGCs). The activity of cetuximab in terms of clinical benefit rate (CBR) def

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d99256dc29f1b7eff5002f6c379c5b41
http://hdl.handle.net/11379/515342

Zobrazit plný text záznamu

Feasibility and activity of docetaxel, cisplatinum and 5-fluorouracil induction chemotherapy followed by concurrent chemo-radiotherapy (including IMRT) in locally advanced undifferentiated nasopharyngeal cancer (LANPC)

Autor: C. Fallail, Lisa Licitra, R Olmi, Paolo Bossi, Mauro Palazzi, C. Liberatoscioli, Cristiana Bergamini, Ester Orlandi, Laura D. Locati

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::668e8c842a9be976fd1e294891c46638
http://hdl.handle.net/11379/515308

Zobrazit plný text záznamu

Cetuximab (C225) in recurrent and/or metastatic salivary gland carcinomas (RMSGCs): A monoinstitutional phase II study

Autor: Gaetana Rinaldi, Cristiana Bergamini, M. Losa, S. Pilotti, Laura D. Locati, F. Perrone, Paolo Bossi, Flavio Crippa, C. Liberatoscioli, Lisa Licitra, Paolo Potepan

Publikováno v: Journal of Clinical Oncology. 24:5547-5547

5547 Background: EGFR is expressed in 70% of salivary gland carcinomas (SGC). Investigations of anti EGFR treatment seems rational. Aim: To assess activity of C225 in patients with RMSGCs in terms of clinical benefit (CB), defined as occurrence of ob

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::439e5d155ff8cca73fb472d9057978de
https://doi.org/10.1200/jco.2006.24.18_suppl.5547

Zobrazit plný text záznamu

[Chronobiological study of free thyroid hormones in hypothyroid and hyperthyroid subjects]

Autor: P, De Remigis, A, Damiani, P, Menduni, M T, Guagnano, L, Vianale, M, D'Angelo, A, Bonaduce, F, Di Sciascio, C, Liberatoscioli, S, Sensi

Publikováno v: Bollettino della Societa italiana di biologia sperimentale. 59(1)

Previous reports demonstrate a circadian rhythm of the free thyroid hormones in healthy subjects. In this study we evaluated circadian variation of FT3 and FT4 in hyperthyroid and hypothyroid states. We considered six hyperthyroid patients, six hypot

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::59b67868a11fa42c5a83fd006451d4ee
https://pubmed.ncbi.nlm.nih.gov/6849692

Zobrazit plný text záznamu

Akademický článek

Targeted Therapy in Salivary Gland Cancer: Prevalence of a Selected Panel of Actionable Molecular Alterations in a German Tertiary Referral Center Patient Cohort.

Autor: Linxweiler M; Department of Otorhinolaryngology, Head and Neck Surgery, Saarland University, Kirrbergerstr. 100, Building 6, 66421, Homburg, Saar, Germany. maximilian.linxweiler@uks.eu., Wemmert S; Department of Otorhinolaryngology, Head and Neck Surgery, Saarland University, Kirrbergerstr. 100, Building 6, 66421, Homburg, Saar, Germany., Braun FL; Department of Otorhinolaryngology, Head and Neck Surgery, Saarland University, Kirrbergerstr. 100, Building 6, 66421, Homburg, Saar, Germany., Körner S; Department of Otorhinolaryngology, Head and Neck Surgery, Saarland University, Kirrbergerstr. 100, Building 6, 66421, Homburg, Saar, Germany., Brust LA; Department of Otorhinolaryngology, Head and Neck Surgery, Saarland University, Kirrbergerstr. 100, Building 6, 66421, Homburg, Saar, Germany., Knebel M; Department of Otorhinolaryngology, Head and Neck Surgery, Saarland University, Kirrbergerstr. 100, Building 6, 66421, Homburg, Saar, Germany., Klamminger GG; Department of General and Surgical Pathology, Saarland University Medical Center, Homburg, Saar, Germany., Wagner M; Department of General and Surgical Pathology, Saarland University Medical Center, Homburg, Saar, Germany., Morris LGT; Department of Surgery, Memorial Sloan Kettering Cancer Center, New York City, NY, USA.; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York City, NY, USA., Kühn JP; Department of Otorhinolaryngology, Head and Neck Surgery, Saarland University, Kirrbergerstr. 100, Building 6, 66421, Homburg, Saar, Germany.

Publikováno v: Molecular diagnosis & therapy [Mol Diagn Ther] 2024 Nov 01. Date of Electronic Publication: 2024 Nov 01.

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání